Russell W Madison

26PUBLICATIONS

170CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Radiation therapyPredictive and prognostic markersMolecular targetsLiquid biopsies

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (26)

Sort by Publication Date:

|Jul 13, 2026

Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

|May 31, 2026

Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial.

|May 07, 2026

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

|Jun 04, 2025

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.

Philip C Mack, Mary W Redman, Hanna Tukachinsky

|May 28, 2025

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab.

Charles Swanton, Russell W Madison, Candice Francheska B Tambaoan

|Mar 25, 2024

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation.

Christian D Rolfo, Russell W Madison, Lincoln W Pasquina

Pageof 5

Frequent Collaborators

Geoffrey R Oxnard

Alexa B Schrock

Jessica K Lee

Lincoln W Pasquina

Jeffrey S Ross

Garrett M Frampton

Brian M Alexander

Siraj M Ali

Hanna Tukachinsky

Andrea Necchi

Frequent Collaborators

Geoffrey R Oxnard

Alexa B Schrock

Jessica K Lee

Lincoln W Pasquina